Kiniksa Pharmaceuticals International (KNSA) vs Rhythm Pharmaceuticals (RYTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Rhythm Pharmaceuticals (RYTM) over the past year, gaining 104.1% versus a loss of 11.4%. Over five years, RYTM leads with a +682.1% price change compared with +580.9% for KNSA. Rhythm Pharmaceuticals is the larger company by market cap ($6.09 billion vs $6.08 billion), about 1.0 times the size, while Kiniksa Pharmaceuticals International is growing revenue faster (+60.1% vs +45.8%).
Kiniksa Pharmaceuticals International converts more of its revenue into profit, with a net margin of 8.7% versus -103.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KNSA | RYTM |
|---|---|---|
| Share price | $77.96 | $88.45 |
| Market cap | $6.08B | $6.09B |
| 1-day change | +1.13% | -2.56% |
| YTD return | +88.63% | -17.37% |
| 1-year return | +104.12% | -11.40% |
| 5-year return | +580.87% | +682.05% |
| P/E ratio (TTM) | 77.96 | — |
| Forward P/E | 48.20 | — |
| EPS (TTM) | $1.00 | $-3.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $677.56M | $189.76M |
| Revenue growth (YoY) | +60.09% | +45.83% |
| Net income (latest FY) | $59.01M | $-196.54M |
| Gross margin | 88.54% | 89.73% |
| Operating margin | 11.40% | -101.19% |
| Net margin | 8.71% | -103.57% |
| 52-week high | $82.94 | $122.20 |
| 52-week low | $35.20 | $74.50 |
| Distance from 52-week high | -6.00% | -27.62% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +25.71% | +56.69% |
| Average volume | 589.58K | 646.31K |
| Shares outstanding | 48.29M | 68.85M |
| Employees | 366 | 414 |
| Sector | Healthcare | Health Care |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KNSA has outperformed RYTM by 115.5 percentage points over the past year.
- Kiniksa Pharmaceuticals International is more profitable, keeping 8.7 cents of every revenue dollar as net income versus -103.6 cents for Rhythm Pharmaceuticals.
- Kiniksa Pharmaceuticals International grew revenue faster in its latest fiscal year (+60.09% vs +45.83%).
- The two companies sit in different sectors: Kiniksa Pharmaceuticals International in Healthcare and Rhythm Pharmaceuticals in Health Care.
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Healthcare · Drug Manufacturers - Specialty & Generic · 366 employees
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
KNSA vs RYTM FAQ
Which is bigger, Kiniksa Pharmaceuticals International or Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals (RYTM) is larger, with a market capitalization of $6.09B compared with $6.08B for Kiniksa Pharmaceuticals International (KNSA).
Which stock has performed better over the past year, KNSA or RYTM?
KNSA returned +104.12% over the past 12 months, compared with -11.40% for RYTM (price return, excluding dividends). Past performance does not predict future results.
Are Kiniksa Pharmaceuticals International and Rhythm Pharmaceuticals in the same industry?
No. Kiniksa Pharmaceuticals International is in the Healthcare sector, while Rhythm Pharmaceuticals is in Health Care.